Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example

Sachs, Jeffrey R., Mayawala, Kapil, Gadamsetty, Satvik, Kang, Soonmo Peter, de Alwis, Dinesh P. · 2016 · Clinical Cancer Research

Published version of a preprint

Abstract

One of the key objectives of oncology first-in-human trials has often been to establish the maximum tolerated dose (MTD). However, targeted therapies might not exhibit dose-limiting toxicities (DLT) at doses significantly higher than sufficiently active doses, and there is frequently a limited ability to objectively quantify adverse events. Thus, while MTD-based determination of recommended phase II dose may have yielded appropriate dosing for some cytotoxics, targeted therapeutics (including monoclonal antibodies and/or immunotherapies) sometimes need alternative or complementary strategies to help identify dose ranges for a randomized dose-ranging study. One complementary strategy is to define a biologically efficacious dose (BED) using an “effect marker.” An effect marker could be a target engagement, pharmacodynamic, or disease progression marker (change in tumor size for solid tumors or bone marrow blast count for some hematologic tumors). Although the concept of BED has been discussed extensively, we review specific examples in which the approach influenced oncology clinical development. Data extracted from the literature and the examples support improving dose selection strategies to benefit patients, providers, and the biopharmaceutical industry. Although the examples illustrate key contributions of effect markers in dose selection, no one-size-fits-all approach to dosing can be justified. Higher-than-optimal dosing can increase toxicity in later trials (and in clinical use), which can have a negative impact on efficacy (via lower adherence or direct sequelae of toxicities). Proper dose selection in oncology should follow a multifactorial decision process leading to a randomized, dose-ranging study instead of a single phase II dose. Clin Cancer Res; 22(6); 1318–24. ©2015 AACR.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-15-1295

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 33 references

Research works printed but not linked: 1

  1. American Association for Cancer Research, 2015, Proceedings of the FDA-AACR Meeting (Dose-finding of small molecule oncology drugs); 2015 May 18–19

Cited by

See all 159

Metadata

Authors
Sachs, J. R., Mayawala, K., Gadamsetty, S., Kang, S. P., & de Alwis, D. P.
Affiliations
  • Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
  • 2Department of PPDM-Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc., Rahway, New Jersey.
Venue
Clinical Cancer Research
Published
2016-03-14
Volume
22
Issue
6
Pages
1318-1324
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2173235643
Cited by
159
References
33
Citations by year
2026: 12 · 2025: 19 · 2024: 24 · 2023: 12 · 2022: 15 · 2021: 7 · 2020: 15 · 2019: 16 · 2018: 15 · 2017: 14 · 2016: 10
FWCI
2.19
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • University of Texas MD Anderson Cancer Center
  • National Cancer Institute
Topics
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
targeted therapy, dose selection, dose-limiting toxicity, maximum tolerated dose, dose-ranging, pharmacodynamic biomarkers, target engagement, monoclonal antibodies, immunotherapy, anticancer drug development, hematologic malignancies, solid tumors
MeSH terms
Animals, Antineoplastic Agents, Dose-Response Relationship, Drug, Humans, Neoplasms, Prognosis, Biomarkers, Treatment Outcome, Maximum Tolerated Dose, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-15-1295
The paper
Sachs, J. R., Mayawala, K., Gadamsetty, S., Kang, S. P., & de Alwis, D. P. (2016). Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-15-1295

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.